13F Holdings
中文EN

BDSX BIODESIX INC

Services-Medical Laboratories · Nasdaq · SEC CIK 1439725 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY31.2%
TTM net income YoY31.5%
TTM EPS YoY49.0%
Revenue 3-yr CAGR33.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-18.7%
Net margin-25.7%
FCF margin-18.1%
EBITDA margin-13.4%

Returns

ROE-778.9%
ROA-29.6%
ROIC (approx.)-50.2%
Asset turnover1.15x

Leverage & solvency

Liabilities / assets90.8%
Debt / equity5.76x
Current ratio2.96x
Interest coverage-2.45x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-9.8%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$88.50M$71.32M$49.09M$38.21M$54.51M
R&D expense$12.00M$9.56M$9.99M$13.10M$12.79M
SG&A expense$87.55M$80.45M$67.39M$61.46M$50.52M
Operating income-$27.87M-$34.50M-$41.34M-$50.59M-$40.94M
Interest expense$7.72M$8.26M$9.54M$8.07M$4.51M
Income tax$0$0$0$0$0
Net income-$35.27M-$42.93M-$52.15M-$65.45M-$43.16M
EBITDA-$22.20M-$28.73M-$38.01M-$46.99M-$37.76M
EPS (basic)-4.67-6.64-0.64-1.55-1.58
EPS (diluted)-4.67-6.64-0.64-1.55-1.58
Weighted avg. shares (diluted)7.55M6.47M82.11M42.10M27.36M
Banking
Provision for credit losses$180,000$887,000$497,000——
Balance sheet
Cash & equivalents$18.99M$26.33M$26.37M$43.17M$32.80M
Receivables$9.04M$8.60M$7.68M$5.07M$3.66M
Current assets$32.52M$39.48M$39.68M$53.33M$43.61M
PP&E, net$24.82M$27.83M$27.87M$5.85M$4.18M
Goodwill$15.03M$15.03M$15.03M$15.03M$15.03M
Intangibles$3.88M$5.87M$7.91M$9.80M$11.62M
Total assets$87.48M$97.24M$99.10M$92.91M$76.10M
Current liabilities$17.44M$14.32M$33.42M$22.84M$28.96M
Long-term debt$50.01M$40.03M$40.08M$30.13M$10.07M
Total debt$50.01M$40.03M$40.08M$30.13M$10.07M
Total liabilities$89.94M$76.37M$94.52M$72.30M$56.37M
Shareholders' equity-$2.46M$20.88M$4.58M$20.61M$19.73M
Net debt$31.02M$13.69M$13.71M-$13.05M-$22.72M
Shares outstanding8.25M7.27M96.24M77.61M30.79M
Cash flow statement
Operating cash flow-$23.27M-$48.65M-$22.87M-$44.97M-$28.22M
Capital expenditure$259,000$3.23M$22.92M$3.30M$2.24M
Free cash flow-$23.53M-$51.88M-$45.79M-$48.27M-$30.46M
Investing cash flow-$403,000-$3.44M-$23.06M-$3.53M-$2.55M
Financing cash flow$16.42M$52.05M$29.13M$58.88M$1.26M
Depreciation & amortization$5.67M$5.77M$3.33M$3.60M$3.18M
Stock-based compensation$4.14M$6.64M$5.37M$5.96M$4.94M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.